Drugs / MF-300
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07613684 | Dec 2024 → Oct 2025 | — | Epirium Bio Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MF-300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07613684 ↗ |
| Route | Oral | “Volunteers will receive oral study drug (MF-300 or placebo) single dose administration.” NCT07613684 ↗ |